1. Home
  2. NCV vs ALT Comparison

NCV vs ALT Comparison

Compare NCV & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NCV
  • ALT
  • Stock Information
  • Founded
  • NCV 2003
  • ALT 1997
  • Country
  • NCV United States
  • ALT United States
  • Employees
  • NCV N/A
  • ALT N/A
  • Industry
  • NCV Finance Companies
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • NCV Finance
  • ALT Health Care
  • Exchange
  • NCV Nasdaq
  • ALT Nasdaq
  • Market Cap
  • NCV 326.0M
  • ALT 327.4M
  • IPO Year
  • NCV N/A
  • ALT N/A
  • Fundamental
  • Price
  • NCV $15.11
  • ALT $3.59
  • Analyst Decision
  • NCV
  • ALT Strong Buy
  • Analyst Count
  • NCV 0
  • ALT 6
  • Target Price
  • NCV N/A
  • ALT $17.40
  • AVG Volume (30 Days)
  • NCV 405.1K
  • ALT 2.5M
  • Earning Date
  • NCV 01-01-0001
  • ALT 11-11-2025
  • Dividend Yield
  • NCV 12.48%
  • ALT N/A
  • EPS Growth
  • NCV N/A
  • ALT N/A
  • EPS
  • NCV N/A
  • ALT N/A
  • Revenue
  • NCV N/A
  • ALT $20,000.00
  • Revenue This Year
  • NCV N/A
  • ALT N/A
  • Revenue Next Year
  • NCV N/A
  • ALT $761,880.20
  • P/E Ratio
  • NCV N/A
  • ALT N/A
  • Revenue Growth
  • NCV N/A
  • ALT N/A
  • 52 Week Low
  • NCV $2.84
  • ALT $2.90
  • 52 Week High
  • NCV $3.59
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • NCV 66.45
  • ALT 44.54
  • Support Level
  • NCV $14.65
  • ALT $3.60
  • Resistance Level
  • NCV $15.29
  • ALT $3.82
  • Average True Range (ATR)
  • NCV 0.14
  • ALT 0.17
  • MACD
  • NCV 0.03
  • ALT 0.02
  • Stochastic Oscillator
  • NCV 75.66
  • ALT 47.52

About NCV Virtus Convertible & Income Fund of Beneficial Interest

Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: